Craft

OBI Pharma

Stock Price

NT$66.9

2024-02-22

Market Capitalization

NT$15.2 B

2024-02-22

Revenue

NT$4.7 M

FY, 2022

OBI Pharma Summary

Company Summary

Overview
OBI Pharma (台灣浩鼎) is a bio-pharma company focused on cancer therapeutics. Its leading compound is an immuno-oncology therapeutic vaccine for the treatment of epithelial cancers, such as breast, ovarian, lung, prostate, colon, gastric, and pancreatic cancer. The product pipeline includes both active (vaccine) and passive (monoclonal antibody and antibody drug conjugate) therapeutics.
Type
Public
Status
Active
Founded
2002
HQ
TW | view all locations
Website
http://www.obipharma.com
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Tamon Tseng

    Tamon Tseng, Director

    • Yun Yen

      Yun Yen, Director

      • Ming-Tain Lai

        Ming-Tain Lai, Chief Scientific Officer

        • Howard S. Lee

          Howard S. Lee, Independent Director

          LocationsView all

          3 locations detected

          • Taipei City HQ

            Taiwan

            7f, No. 369, Zhongxiao E Rd, Nangang District

          • San Diego, CA

            United States

            5959 Cornerstone Ct W Suite 200

          • Taipei City

            Taiwan

            No. 3, Yuanqu Street, Nangang District

          OBI Pharma Financials

          Summary Financials

          Revenue (Q3, 2023)
          NT$11.5M
          Gross profit (Q3, 2023)
          (NT$16.5M)
          Net income (Q3, 2023)
          (NT$613.5M)
          Cash (Q3, 2023)
          NT$2.1B
          EBIT (Q3, 2023)
          (NT$707.8M)
          Enterprise value
          $13.6B

          Footer menu